The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6...
PREVENTION | MEDICINE, GENERAL & INTERNAL | INTERHEART | MYOCARDIAL-INFARCTION | 52 COUNTRIES | CATARACT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - ethnology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Male | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Cholesterol | Hypertension | Myocardial infarction | Cerebral infarction | C-reactive protein | Diabetes mellitus | Cardiovascular disease | Lipids | Inflammation | Low density lipoprotein | Disease prevention | Surgery | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Statins
PREVENTION | MEDICINE, GENERAL & INTERNAL | INTERHEART | MYOCARDIAL-INFARCTION | 52 COUNTRIES | CATARACT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - ethnology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Male | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Cholesterol | Hypertension | Myocardial infarction | Cerebral infarction | C-reactive protein | Diabetes mellitus | Cardiovascular disease | Lipids | Inflammation | Low density lipoprotein | Disease prevention | Surgery | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Statins
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or...
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 18, pp. 1744 - 1753
Patients undergoing cardiac surgery were randomly assigned to rosuvastatin or placebo. The groups did not differ significantly in the rate of postoperative...
C-REACTIVE PROTEIN | ENDOTHELIAL PROGENITOR CELLS | MEDICINE, GENERAL & INTERNAL | CORONARY SURGERY | REDOX STATE | CLINICAL-TRIALS | OXIDASE ACTIVITY | POSTOPERATIVE ATRIAL-FIBRILLATION | CARDIOPULMONARY BYPASS | MYOCARDIAL INJURY | RANDOMIZED CONTROLLED-TRIAL | Perioperative Care | Rosuvastatin Calcium - therapeutic use | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Postoperative Complications - prevention & control | Male | Troponin I - blood | Cardiac Surgical Procedures | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - blood | Female | Acute Kidney Injury - chemically induced | Aged | C-Reactive Protein - analysis | Atrial Fibrillation - prevention & control | Elective Surgical Procedures | Heart | Cardiac arrhythmia | Oxidative stress | Heart attacks | Renal function | Kidneys | C-reactive protein | Heart surgery | Mortality | Clinical trials | Preventive medicine | Morbidity | Cholesterol | Troponin | Fibrillation | Troponin I | Calcium-binding protein | Surgery | Ventricle | Drug therapy | Statins
C-REACTIVE PROTEIN | ENDOTHELIAL PROGENITOR CELLS | MEDICINE, GENERAL & INTERNAL | CORONARY SURGERY | REDOX STATE | CLINICAL-TRIALS | OXIDASE ACTIVITY | POSTOPERATIVE ATRIAL-FIBRILLATION | CARDIOPULMONARY BYPASS | MYOCARDIAL INJURY | RANDOMIZED CONTROLLED-TRIAL | Perioperative Care | Rosuvastatin Calcium - therapeutic use | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Postoperative Complications - prevention & control | Male | Troponin I - blood | Cardiac Surgical Procedures | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - blood | Female | Acute Kidney Injury - chemically induced | Aged | C-Reactive Protein - analysis | Atrial Fibrillation - prevention & control | Elective Surgical Procedures | Heart | Cardiac arrhythmia | Oxidative stress | Heart attacks | Renal function | Kidneys | C-reactive protein | Heart surgery | Mortality | Clinical trials | Preventive medicine | Morbidity | Cholesterol | Troponin | Fibrillation | Troponin I | Calcium-binding protein | Surgery | Ventricle | Drug therapy | Statins
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 341 - 355
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure...
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P‐450 enzymes and multiple membrane...
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
Journal Article
AIDS, ISSN 0269-9370, 03/2017, Volume 31, Issue 5, pp. 681 - 688
BACKGROUND:Several studies have shown a significant association between vitamin D deficiency and an increased risk of statin-related symptomatic myalgia in the...
myalgia | statin | Vitamin D | myopathy | antiretroviral therapy | C-REACTIVE PROTEIN | INFECTIOUS DISEASES | RISK-FACTORS | vitamin D | HYPERLIPIDEMIA | INTOLERANCE | IMMUNOLOGY | ATORVASTATIN | MYOSITIS-MYALGIA | VIROLOGY | PRAVASTATIN | DYSLIPIDEMIA | ROSUVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Anti-Retroviral Agents - therapeutic use | Vitamin D Deficiency - complications | Myalgia - chemically induced | Atorvastatin Calcium - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Myalgia - epidemiology | Rosuvastatin Calcium - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Aged | Retrospective Studies | Atorvastatin Calcium - adverse effects | Index Medicus | AIDS/HIV
myalgia | statin | Vitamin D | myopathy | antiretroviral therapy | C-REACTIVE PROTEIN | INFECTIOUS DISEASES | RISK-FACTORS | vitamin D | HYPERLIPIDEMIA | INTOLERANCE | IMMUNOLOGY | ATORVASTATIN | MYOSITIS-MYALGIA | VIROLOGY | PRAVASTATIN | DYSLIPIDEMIA | ROSUVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Anti-Retroviral Agents - therapeutic use | Vitamin D Deficiency - complications | Myalgia - chemically induced | Atorvastatin Calcium - administration & dosage | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Myalgia - epidemiology | Rosuvastatin Calcium - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | HIV Infections - complications | Adult | Female | HIV Infections - drug therapy | Aged | Retrospective Studies | Atorvastatin Calcium - adverse effects | Index Medicus | AIDS/HIV
Journal Article
Epilepsy Research, ISSN 0920-1211, 2017, Volume 135, pp. 64 - 70
Highlights • Rosuvastatin exposure was decreased (∼40%) with concomitant steady-state ESL. • The decreased rosuvastatin exposure may result from reduced oral...
Neurology | Eslicarbazepine | Rosuvastatin | Drug interaction | Antiepileptic drugs | Epilepsy | Pharmacokinetic | ATP-DEPENDENT TRANSPORT | RISK | Pharmacoldnetic | STATINS | DISPOSITION | CLINICAL NEUROLOGY | DRUG-DRUG INTERACTION | PREMATURE MORTALITY | CANCER RESISTANCE PROTEIN | LIPIDS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Follow-Up Studies | Area Under Curve | Dibenzazepines - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Biological Availability | Male | Rosuvastatin Calcium - administration & dosage | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Anticonvulsants - adverse effects | Drug Interactions | Adult | Female | Membrane Transport Proteins - metabolism | Rosuvastatin Calcium - blood | Anticonvulsants - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Dibenzazepines - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Least-Squares Analysis | Dosage and administration | Analysis | Drug interactions | Antilipemic agents
Neurology | Eslicarbazepine | Rosuvastatin | Drug interaction | Antiepileptic drugs | Epilepsy | Pharmacokinetic | ATP-DEPENDENT TRANSPORT | RISK | Pharmacoldnetic | STATINS | DISPOSITION | CLINICAL NEUROLOGY | DRUG-DRUG INTERACTION | PREMATURE MORTALITY | CANCER RESISTANCE PROTEIN | LIPIDS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Follow-Up Studies | Area Under Curve | Dibenzazepines - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Biological Availability | Male | Rosuvastatin Calcium - administration & dosage | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Anticonvulsants - adverse effects | Drug Interactions | Adult | Female | Membrane Transport Proteins - metabolism | Rosuvastatin Calcium - blood | Anticonvulsants - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Dibenzazepines - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Least-Squares Analysis | Dosage and administration | Analysis | Drug interactions | Antilipemic agents
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 3, pp. 286 - 294
Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to...
Rosuvastatin calcium | Candesartan cilexetil | Bioequivalence study | Angiotensin receptor blocker | Fixed-dose combination | HMG-CoA reductase | EFFICACY | rosuvastatin calcium | VOLUNTEERS | angiotensin receptor blocker | OPEN-LABEL | fixed-dose combination | STATINS | candesartan cilexetil | bioequivalence study | 2-PERIOD | PHARMACOLOGY & PHARMACY | CROSSOVER | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tablets | Area Under Curve | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Tetrazoles - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Adult | Biphenyl Compounds - blood | Benzimidazoles - adverse effects | Rosuvastatin Calcium - blood | Benzimidazoles - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Benzimidazoles - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Biphenyl Compounds - administration & dosage | Angiotensin II Type 1 Receptor Blockers - blood | Tetrazoles - adverse effects | Drug Combinations | Tetrazoles - pharmacokinetics | Therapeutic Equivalency | Pharmaceutical industry
Rosuvastatin calcium | Candesartan cilexetil | Bioequivalence study | Angiotensin receptor blocker | Fixed-dose combination | HMG-CoA reductase | EFFICACY | rosuvastatin calcium | VOLUNTEERS | angiotensin receptor blocker | OPEN-LABEL | fixed-dose combination | STATINS | candesartan cilexetil | bioequivalence study | 2-PERIOD | PHARMACOLOGY & PHARMACY | CROSSOVER | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tablets | Area Under Curve | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Tetrazoles - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Adult | Biphenyl Compounds - blood | Benzimidazoles - adverse effects | Rosuvastatin Calcium - blood | Benzimidazoles - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Benzimidazoles - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Biphenyl Compounds - administration & dosage | Angiotensin II Type 1 Receptor Blockers - blood | Tetrazoles - adverse effects | Drug Combinations | Tetrazoles - pharmacokinetics | Therapeutic Equivalency | Pharmaceutical industry
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 525 - 533
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter‐mediated accumulation in the liver enhances its efficacy....
VARIABILITY | DRUG | ACID | PHARMACOKINETICS | TRANSPORTERS | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | PHARMACODYNAMICS | POLYMORPHISM | ATORVASTATIN | Dyslipidemias - genetics | Prospective Studies | Rosuvastatin Calcium - therapeutic use | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Dyslipidemias - ethnology | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Neoplasm Proteins - metabolism | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Canada - epidemiology | Fasting - blood | Postprandial Period | Pharmacogenomic Variants | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Dyslipidemias - drug therapy | European Continental Ancestry Group - genetics | Risk Assessment | Rosuvastatin Calcium - pharmacokinetics | Down-Regulation | Food-Drug Interactions | Mice, Inbred C57BL | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Treatment Outcome | Biomarkers - blood | Cross-Over Studies | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mice | Muscular Diseases - genetics
VARIABILITY | DRUG | ACID | PHARMACOKINETICS | TRANSPORTERS | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | PHARMACODYNAMICS | POLYMORPHISM | ATORVASTATIN | Dyslipidemias - genetics | Prospective Studies | Rosuvastatin Calcium - therapeutic use | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Dyslipidemias - ethnology | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Neoplasm Proteins - metabolism | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Canada - epidemiology | Fasting - blood | Postprandial Period | Pharmacogenomic Variants | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Dyslipidemias - drug therapy | European Continental Ancestry Group - genetics | Risk Assessment | Rosuvastatin Calcium - pharmacokinetics | Down-Regulation | Food-Drug Interactions | Mice, Inbred C57BL | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Treatment Outcome | Biomarkers - blood | Cross-Over Studies | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mice | Muscular Diseases - genetics
Journal Article
Pharmacological Research, ISSN 1043-6618, 05/2016, Volume 107, pp. 1 - 18
Abbreviations: IL-6: interleukin-6; NO: nitric oxide; LDL-C: low-density lipoprotein-cholesterol; TC: total cholesterol; VLDL: very low-density...
Pleiotrophic effect | Cardiovascular disease | Lipid-lowering effect | Rosuvastatin | C-REACTIVE PROTEIN | CHRONIC HEART-FAILURE | COA REDUCTASE INHIBITORS | FATTY LIVER-DISEASE | LOW-DENSITY-LIPOPROTEIN | HYDROPHILIC STATIN THERAPY | HUMAN ENDOTHELIAL-CELLS | PERCUTANEOUS CORONARY INTERVENTION | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Rosuvastatin Calcium - therapeutic use | Anti-Inflammatory Agents - pharmacology | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Rosuvastatin Calcium - adverse effects | Rosuvastatin Calcium - pharmacology | Antioxidants - pharmacology | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - pharmacology | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Fibrinolytic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Antioxidants - adverse effects | Enzymes | Interleukins | Low density lipoproteins | Nitric oxide | Cholesterol | Anticholesteremic agents | Antioxidants | Thiols | Analysis | Liver | Transplantation of organs, tissues, etc | Cardiovascular agents
Pleiotrophic effect | Cardiovascular disease | Lipid-lowering effect | Rosuvastatin | C-REACTIVE PROTEIN | CHRONIC HEART-FAILURE | COA REDUCTASE INHIBITORS | FATTY LIVER-DISEASE | LOW-DENSITY-LIPOPROTEIN | HYDROPHILIC STATIN THERAPY | HUMAN ENDOTHELIAL-CELLS | PERCUTANEOUS CORONARY INTERVENTION | ACUTE MYOCARDIAL-INFARCTION | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | Rosuvastatin Calcium - therapeutic use | Anti-Inflammatory Agents - pharmacology | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Rosuvastatin Calcium - adverse effects | Rosuvastatin Calcium - pharmacology | Antioxidants - pharmacology | Fibrinolytic Agents - adverse effects | Fibrinolytic Agents - pharmacology | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Fibrinolytic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Antioxidants - adverse effects | Enzymes | Interleukins | Low density lipoproteins | Nitric oxide | Cholesterol | Anticholesteremic agents | Antioxidants | Thiols | Analysis | Liver | Transplantation of organs, tissues, etc | Cardiovascular agents
Journal Article